A review of the updated European Best Practice Guidelines for the Management Of Anaemia in Patients with Chronic Renal Failure

EDTNA-ERCA Journal

Volumn 31, Issue 3, 2005, Pages 156-159

  Jenkins, Karen ^a,b  

^a KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^b ANSA (Anaemia Nurse Specialist Association)   (United Kingdom)

Author keywords

Anaemia; Chronic kidney disease; Evidence based practice; Guidelines; Targets

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CARNITINE; CREATININE; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DISEASE COURSE; EUROPE; EVIDENCE BASED MEDICINE; FERRITIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HEMODIALYSIS; HUMAN; IRON THERAPY; MEDICAL SOCIETY; NUTRITIONAL STATUS; PATIENT REFERRAL; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PURE RED CELL ANEMIA; QUALITY OF LIFE; RETICULOCYTE COUNT; REVIEW; SYSTEMATIC REVIEW;

EID: 29044436900     PISSN: 1019083X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2005.tb00418.x     Document Type: Review

References (17)

1. Levin A, Thompson CR, Either J et al. Left ventricular mass index increases in early renal disease: impact of decline in haemoglobin. American Journal of Kidney disease 1999; 34: 125-134.
2. Foley RN, Parfrey PS, Morgan J et al. Effect of haemoglobin levels in haemodialysis patients with asymptomatic cardiomyopathy. Kidney International 2000; 58: 1325-1335.
3. Silverberg DS, Wexler D, Blum M et al. The effects of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrology, Dialysis Transplantation 2003; 18: 141-146.
4. Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrology, Dialysis Transplantation 2000; 15: 23-28.
5. European Best Practice Guidelines for Management of anaemia in patients with chronic renal failure. Nephrology, Dialysis Transplantation 1999; 14 (suppl 5) S1-S50.
6. Revised European Best Practice Guidelines for Management of anaemia in patients with chronic renal failure. Nephrology, Dialysis Transplantation 2004; 19; (suppl 2) S1-S47.
7. Cockcroft DW, Gault MH, Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine; a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of International Medicine 1999; 130: 461-470.
9. K/DOQI clinical practice guideline for chronic kidney disease evaluation, classification, and stratification. American Journal of Kidney Disease 2002; 39 (suppl 1) S1-S266.
10. th Ed. Little Brown & Co. Boston; 1994: 253-256.
11. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The Safety of intravenous iron dextran in hemodialysis patients. American Journal of Kidney Disease 1996; 28: 529-534.
12. Vanrenterghem Y, Barany P, Mann JF et al. Randomised trial of darbepoetin alfa for treatment of renal anaemia at reduced dose frequency compared with rHuEPO in dialysis patients. Kidney International 2002; 62: 2167-2175.
13. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEPO). Nephrology, Dialysis Transplantation 2003; 18: 362-369.
14. Kopple JD. National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. American Journal of Kidney Disease 2001b; 37 (1 Suppl 2) S66-S70.
15. Horl WH. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrology, Dialysis Transplantation 1999; 14: (suppl 2): 50-60.
16. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney International 1999; 55: 2477-2486.
17. Casadevall N. Antobodies against rHuEPO: native and recombinant. Nephrology, Dialysis Transplantation 2002; 17: (suppl 5): 42-47.